{"url_path":"/sec/klrs/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-219328-index.html","accession_number":"0001193125-26-219328","cik":"0001754068","ticker":"KLRS","issuer_name":"Kalaris Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-219328-index.html","primary_entity_key":"0001754068","primary_entity_name":"Kalaris Therapeutics, Inc."},"word_count":195,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings.\n\nLitigation Related to the Merger\n\nTwo complaints have been filed by purported AlloVir stockholders as individual actions against AlloVir and the members of its board of directors in the Supreme Court of the State of New York, New York County, captioned Keller v. AlloVir, Inc. et al., No. 650989/2025 (N.Y. Sup. Ct. Feb. 20, 2025), and Morgan v. AlloVir, Inc. et al., No. 650965/2025 (N.Y. Sup. Ct. Feb. 19, 2025) (the “Complaints”). The Complaints allege that the proxy statement/prospectus describing the transaction between Legacy Kalaris and AlloVir misrepresented and/or omitted certain purportedly material information, and assert claims for negligent misrepresentation and concealment and negligence under New York common law. The Complaints seek various remedies including, among other things, an order enjoining the consummation of the merger, requiring the defendants to file an amended proxy statement/prospectus, rescinding the merger or granting rescissory damages, and awarding costs, including plaintiff’s attorneys’ fees and experts’ fees, and other relief the court may deem just and proper. AlloVir and Legacy Kalaris deny the allegations in the Complaints and deny that any further disclosure beyond that already contained in the proxy statement/prospectus was required under applicable law."}